Table 2 List of relevant studies from literature
Author and year | Study patients | Age at presentation Mean (± SD)/median (range) | BMI Mean (± SD)/median (range) | OA severity (K-L grade/ACR criteria) | Intraarticular injection and number | Follow-up (months) Mean (± SD)/median (range) | Outcome measures | Adverse events (AE)/complications | Level of evidence |
|---|---|---|---|---|---|---|---|---|---|
Kon et al. 2018 [22] | 46 | 57 (41–68) | NR | K-L 2–3 | APS 1 | 12 (± NR) | WOMAC VAS KOOS SF-36 CGI-S/PGI-S | AE – 6 Arthralgia | 2 |
Tassara et al. 2018 [24] | 25 | 68 (34–87) | NR | NR | ACS 4 | 6 (± NR) | VAS ROM | None | 3 |
Zarringam et al. 2018 [23] | 126 | 63 (NR) | NR | K-L 1–3 | ACS 6 | 90 (± 47) | K-M | NR | 3 |
100 | 61.2 (± 1.2) | 33.8 (± 1.4) | ACR | ACS 6 | 12 (± NR) | VAS XSMFA-D PGIC | NR | 3 | |
Hang et al. 2017 [33] | 92 | NR | NR | NR | ACS 4 | 12 (± NR) | VAS WOMAC | NR | 3 |
Shirokova et al. 2017 [34] | 123 | 59.9 (± 8.8) | NR | ACR | ACS 6 | 3 (± NR) | VAS WOMAC | NR | 3 |
Hix et al. 2017 [20] | 10 | 58.8 (± 9.5) | 29.0 (± 3.9) | NR | APS 1 | 12 (± NR) | WOMAC KOOS NRS | AE – 4 Arthralgia Discomfort | 3 |
van Drumpt et al. 2016 [21] | 10 | 57.5 (± 9.5) | 26.6 (± 3.1) | K-L 1–4 | APS 1 | 18 (± 1) | WOMAC | AE – 6 Arthralgia Joint stiffness Injection site pain | 3 |
Garcia-Escudero et al. 2015 [35] | 118 | 59 (34–81) | 29.6 (± NR) | K-L 1–4 | ACS 4 | 24 (± NR) | WOMAC NRS | None | 3 |
Rutgers et al. 2015 [36] | 20 | 50 (34–70) | NR | K-L 1–3 | ACS 6 | 12 (± NR) | VAS KOOS KSCRS | NR | 3 |
Motaal et al. 2014 [37] | 30 | 54.21 (± 5.95) | NR | K-L 1–3 | ACS 3 | 3 (± NR) | WOMAC | NR | 3 |
Baltzer et al. 2009 [38] | 376 | 53.8 (± 12.2) | NR | K-L 2–3 | ACS 6 | 25 (± NR) | WOMAC SF-8 VAS | AE – 31 Joint swelling Transient pain | 2 |
Yang et al. 2008 [39] | 153 | 54 (± 11) | 27 (± 5) | K-L 1–3 | ACS 6 | 12 (± NR) | WOMAC KSCRS | Knee pain – 44 Irritation – 70 Swelling – 10 Septic arthritis – 1 | 2 |